MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · IEX Real-Time Price · USD
3.350
-0.090 (-2.62%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Company Description
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc.
Country | United States |
Founded | 2018 |
IPO Date | Jul 28, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Dr. Vlad Vitoc M.B.A., M.D. |
Contact Details
Address: 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 United States | |
Phone | 312-416-8592 |
Website | MAIABiotech.com |
Stock Details
Ticker Symbol | MAIA |
Exchange | NYSEAMERICAN |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001878313 |
CUSIP Number | 552641102 |
ISIN Number | US5526411021 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors |
Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
Jeffrey C. Himmelreich | Head of Finance |
Linda Moreira | Company Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 6, 2024 | 8-K | Current Report |
Jun 4, 2024 | 8-K | Current Report |
Jun 3, 2024 | 8-K | Current Report |
May 29, 2024 | 8-K | Current Report |
May 15, 2024 | 8-K | Current Report |
May 15, 2024 | 424B5 | Filing |
May 14, 2024 | 10-Q | Quarterly Report |
May 7, 2024 | 8-K | Current Report |
Apr 23, 2024 | 8-K | Current Report |
Apr 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |